Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Andrew D. Bowser

    News

    Phase 2 studies show potential of FcRn blockade in primary ITP

    Author:
    Andrew D. Bowser
    Publish date: December 12, 2019

    ORLANDO – The results support continued investigation in phase 3 trial for rozanolixizumab and efgartigimod, according to investigators.

    • Read More

    News

    New ASH guideline: VTE prophylaxis after major surgery

    Author:
    Andrew D. Bowser
    Publish date: December 12, 2019

    ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...

    • Read More

    News

    Fibrosis scoring systems have ‘modest’ predictive value in general population

    Author:
    Andrew D. Bowser
    Publish date: December 10, 2019

    For predicting severe liver disease, investigators say today’s scoring systems lack precision in unselected populations with low prevalence of...

    • Read More

    News

    Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL

    Author:
    Andrew D. Bowser
    Publish date: December 10, 2019

    ORLANDO – The multicenter study was aimed at addressing the knowledge gap around what therapy to use after venetoclax.

    • Read More

    News

    Fragmentation of sickle cell disease care starts in young adulthood

    Author:
    Andrew D. Bowser
    Publish date: December 8, 2019

    ORLANDO – Imagine what that would be like to have a chronic, debilitating illness and to have to go to multiple different hospitals, during this...

    • Read More

    News

    Kidney function in African American AML patients not linked to reduced survival compared with whites

    Author:
    Andrew D. Bowser
    Publish date: December 7, 2019

    ORLANDO – Liberalizing renal function eligibility criteria might promote recruitment of African Americans to AML...

    • Read More

    News

    Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma

    Author:
    Andrew D. Bowser
    Publish date: December 7, 2019

    ORLANDO – Duration of response, manageable safety support further investigation of dual-targeted strategy, according to investigator.

    • Read More

    News

    UC: Tofacitinib tied to modest, reversible lipid increases, infrequent CV events

    Author:
    Andrew D. Bowser
    Publish date: December 6, 2019

    The observation period was still relatively short, however so longer-term data may be needed to more fully characterize lipid impact and...

    • Read More

    News

    No clear-cut evidence of vedolizumab effect in retrospective study of primary sclerosing cholangitis

    Author:
    Andrew D. Bowser
    Publish date: December 6, 2019

    Cholestasis markers dropped in some, but not all, patients with primary sclerosing cholangitis and inflammatory bowel disease, though a...

    • Read More

    News

    Early colonoscopy for acute lower GI bleeding fails to improve diagnostic yield or reduce rebleeding rate

    Author:
    Andrew D. Bowser
    Publish date: December 3, 2019

    Compared with elective colonoscopy, recommended procedure resulted in no statistical difference in primary or key secondary outcome.

    • Read More

    News

    What’s new in hepatitis C: Four themes that dominated at the Liver Meeting

    Author:
    Andrew D. Bowser
    Publish date: November 22, 2019

    BOSTON – AASLD highlights included treatment of persons who inject drugs, new directions in pangenotypic therapy,...

    • Read More

    News

    Skin barrier dysfunction mutations vary by race, disease persistence in children with AD

    Author:
    Andrew D. Bowser
    Publish date: November 21, 2019

    Findings may have implications for genetic test development, investigators note.

    • Read More

    News

    AASLD debrief: Five drugs show promise in NAFLD (and two do not)

    Author:
    Andrew D. Bowser
    Publish date: November 21, 2019

    BOSTON – Promising new data for cotadutide, licogliflozin, tropifexor, saroglitazar, and PF-05221304 highlighted in...

    • Read More

    News

    TARGET-NASH: One-third of NAFLD, NASH patients lost weight, but not all kept it off

    Author:
    Andrew D. Bowser
    Publish date: November 20, 2019

    BOSTON – With no approved pharmacologic treatments for NAFLD and NASH, weight reduction remains one of the mainstays of treatment.

    • Read More

    News

    Ask about vaping in patients with respiratory symptoms, CDC says

    Author:
    Andrew D. Bowser
    Publish date: November 20, 2019

    New CDC recommendations intended to help HCPs pinpoint and manage vaping-associated lung injuries as seasonal respiratory infections trend upward...

    • Read More

    Pages

    • « first
    • …
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery